Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis. We assessed the efficacy and durability of short and prolonged CVC therapy in a diet‐induced mouse model of NASH, the choline deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) model. C57BL/6 mice received 4 or 14 weeks of standard chow or the CDAHFD. CVC (10 mg/kg/day and 30 mg/kg/day for 4 weeks and 20 mg/kg/day and 30 mg/kg/day for 14 weeks) was initiated simultaneously with the CDAHFD. At 4 and 14 weeks, livers were harvested for histology and flow cytometric analyses of intrahepatic immune cells. High‐dose CVC (30 mg/kg/day) therapy in CDAHFD mice for 4 or 14 weeks inhibited intrahepatic accumulation of Ly6C high bone marrow‐derived macrophages. Prolonged CVC therapy (14 weeks) yielded no significant differences in the total intrahepatic macrophage populations among treatment groups but increased the frequency of intrahepatic anti‐inflammatory macrophages in the high‐dose CVC group. Despite ongoing steatohepatitis, there was significantly less fibrosis in CDAHFD mice receiving high‐dose CVC for 14 weeks based on histologic and molecular markers, mirroring observations in human NASH CVC trials. CVC also directly inhibited the profibrotic gene signature of transforming growth factor‐β‐stimulated primary mouse hepatic stellate cells in vitro. Conclusion: CVC is a novel therapeutic agent that is associated with reduced fibrosis despite ongoing steatohepatitis. Its ability to alter intrahepatic macrophage populations and inhibit profibrogenic genes in hepatic stellate cells in NASH livers may contribute to its observed antifibrotic effect. (Hepatology Communications 2018;2:529‐545)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503 · cited 1×
“, CCR2, CCL2, and chemokine C-X-C motif ligand 16, prevents steatohepatitis and fibrosis in mice fed a steatotic diet by inhibiting inflammatory monocyte trafficking.((8-10)) Although chemokine antagonism is an attractive therapeutic target, it is also a highly redundant system, raising concerns that a singular CCR/CC…”
BackgroundLefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · cited 3×
“The streptozotocin plus high-fat diet model is limited by a lack of progressive fibrosis, and CVC therapy was only continued for a short-term period (9 weeks) in this dietary model.((12)) Because future NASH therapies in humans, including CVC, may be required for the long term, due to the challenge of adherence to lon…”
BackgroundSelf-citationKleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Localized CCR2 Activation in the Bone Marrow Niche Mobilizes Monocytes by Desensitizing CXCR4
Jung, H., Mithal, D. S., Park, J. E., & Miller, R. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128387 · Cited by 68 · cited 1×
“CVC is known to specifically inhibit the CCL2CCR2-mediated activation and homing of bone marrow-derived monocytes.((12,17)) Therefore, we hypothesized that CVC blockade should prevent trafficking of bone marrow-derived (defined as Ly6C) monocytes to the liver.”
Background
Cited by
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Anstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.003 · Cited by 179
The Space of Disse: The Liver Hub in Health and Disease
Sanz-García, C., Fernández-Iglesias, A., Gracia-Sancho, J., Arráez-Aybar, L. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Livers · doi:10.3390/livers1010002 · Cited by 57
Sojoodi, M., Erstad, D. J., Barrett, S. C., Salloum, S., Zhu, S., Qian, T., Colon, S., Gale, E. M., Jordan, V. C., Wang, Y., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.01.015 · Cited by 35
Self-citationKohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Metadata
- Authors
- Kruger, A. J., Fuchs, B. C., Masia, R., Holmes, J. A., Salloum, S., Sojoodi, M., Ferreira, D. S., Rutledge, S. M., Caravan, P., Alatrakchi, N., Vig, P., Lefebvre, E., & Chung, R. T.
- Venue
- Hepatology Communications
- Published
- 2018-03-07
- Volume
- 2
- Issue
- 5
- Pages
- 529-545
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2791821840
- Cited by
- 66
- References
- 4
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.